Business & Industry
BioPharma
CDMOs Must Reorganize to Maximize Revenue and Competitiveness
Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...
Business & Industry
Thermo Fisher to Acquire Clario Holdings for $8.9bn
Thermo Fisher to acquire Clario Holdings, the clinical trial data firm,ย for $8.9 billion in cash is in news and the same has been announced by the companies on October 29. Clario is at present held by a shareholder group...
Business & Industry
Simtra BioPharma Expands High-Quality Sterile Injectables
One of the leading contract development and manufacturing organization โ CDMO that specializes in high-quality sterile injectables, Simtra BioPharma Solutions, has made tremendous progress on a dual-continent expansion strategy in order to meet the growing global demand for intricate...
Business & Industry
API China Strengthens its Role as Asiaโs Pharma Powerhouse
Heads to Chongqing for its 93rdย edition
API China, Asiaโs authoritative exhibition for pharmaceutical ingredients and manufacturing, will convene its 93rdย editionย at the Chongqing International Expo Center from 12โ14 November 2025. Held twice annually, the event is one of the largest gatherings...
Business & Industry
Kindeva Announces the Appointment of David Stevens as President
Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to the newly created role of President. In this capacity, David will lead Kindevaโs global...
Business & Industry
J&J To Be in Sync with Trump Administration as MFN Spreads
As the two Trump administration drug pricing deals find their place in the books and more that are likely on the way, the U.S. policy environment can very well soon stabilize for many Big Pharma companies. All this puts...
BioPharma
Investments in the U.S. of Over $70bn Announced by Merck
It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















